This article provides an in-depth analysis of Ph. Eur. Monograph 0478, exploring its scope, core quality requirements, critical testing methodologies, and its profound impact on pharmaceutical manufacturing and regulatory compliance. 1. Scope and Definition of Monograph 0478
The Ph. Eur. actively works with other major pharmacopoeias (like the and Japanese Pharmacopoeia ) through the Pharmacopoeial Discussion Group (PDG) to harmonize standards wherever possible. This global harmonization is guided by principles such as those outlined in the ICH Q6A guideline on specifications, and it represents a continuous effort to align key tests like disintegration.
Ph. Eur. 0478 allows a "re-test" for disintegration (repeat on 6 new tablets) if 1-2 of the first 6 fail. USP <701> requires that if 1-2 fail, you test 12 more; if more than 2 fail initially, rejection is immediate. European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-
Monograph 0478 does not specify which chemical identity test to use (that is left to the individual active substance monograph). However, it mandates that the must be capable of distinguishing the tablet from placebo.
user wants a long article about "European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-". I need to provide comprehensive information. I'll break down the search into key aspects: general information about Ph. Eur., the specific Tablets monograph 0478, its content, historical context, and related regulatory guidelines. I'll search in English. search results show several relevant pages. I need to open them to gather detailed information. I'll open the drugfuture.com page (result 0) for the full text of the monograph. I'll also open the GMP Compliance Advisor page (result 2) for the revision history. The EDQM FAQ page (result 1) might provide additional context. The Pink Citeline page (result 5) and the USP page (result 6) might also be useful. I'll open these pages. pages provide a lot of information. The drugfuture.com page gives the full monograph text. The GMP Compliance Advisor page details the 2018 revision. The EDQM FAQ explains disintegration testing. The Pink Citeline PDF discusses dissolution testing policies. The USP PDF provides historical revision data. The AGES study mentions divisibility testing. The WhatDoTheyKnow page discusses break-mark requirements. I need to structure the article. I'll cover the monographs definition and scope, the various categories of tablets, production quality parameters, the evolution of the monograph, its role in regulatory compliance, and future developments. I'll cite the sources appropriately. European Pharmacopoeia (Ph. Eur.) is a foundational text for the quality control of medicines across Europe and beyond. Among its most referenced sections is the general monograph . This monograph defines the legally binding quality standards for one of the most common pharmaceutical dosage forms: the tablet. This article provides an in-depth analysis of Ph
: For tablets with break-marks, the efficacy of the mark is assessed by weighing subdivided parts. Not more than one out of 30 parts may fall outside 85% to 115% of the average mass. 4. Mandatory Pharmacopoeial Tests
The European Pharmacopoeia (Ph. Eur.) serves as the definitive scientific benchmark for the quality control of medicines across Europe and beyond. Among its numerous standards, Monograph 0478, titled simply "Tablets," provides the legal and technical requirements for the most common oral dosage form in modern medicine. actively works with other major pharmacopoeias (like the
If you need a deep dive into the for tests like the Uniformity of Dosage Units (2.9.40)?
To ensure patients receive the intended dose, the break-mark's efficacy must be assessed during product development. The test: break 30 tablets by hand, weigh one part from each, and check mass uniformity. Not more than one part can fall outside 85-115% of the average mass.
Monograph 0478 differentiates testing protocols based on the specialized functionality of the tablet: